PTGER4 and neoplasm: Administration of EP4 antagonists (RQ15986, AH23848, Frondoside A) to tumor bearing mice restores the profound suppression of NK activity (cytotoxic functions, cytokine production, chemotactic activity), even in the context of progressive tumor growth (Holt et al., 2012; Ma et al., 2013).